Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care

dc.contributor.authorApostolova, Liana G.
dc.contributor.authorHaider, Janelle M.
dc.contributor.authorGoukasian, Naira
dc.contributor.authorRabinovici, Gil D.
dc.contributor.authorChetelat, Gael
dc.contributor.authorRingman, John M.
dc.contributor.authorKremen, Sarah
dc.contributor.authorGrill, Joshua
dc.contributor.authorRestrepo, Lucas
dc.contributor.authorMendez, Mario F.
dc.contributor.authorSilverman, Daniel H.
dc.contributor.departmentDepartment of Neurology, IU School of Medicineen_US
dc.date.accessioned2017-05-01T19:32:52Z
dc.date.available2017-05-01T19:32:52Z
dc.date.issued2016-12-18
dc.description.abstractINTRODUCTION: The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. METHODS: Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. RESULTS: Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. DISCUSSION: The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.en_US
dc.identifier.citationApostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., … Silverman, D. H. (2016). Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 5, 15–22. http://doi.org/10.1016/j.dadm.2016.12.001en_US
dc.identifier.urihttps://hdl.handle.net/1805/12391
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.dadm.2016.12.001en_US
dc.relation.journalAlzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoringen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.sourcePMCen_US
dc.subjectAlzheimer's disease (AD)en_US
dc.subjectAmyloiden_US
dc.subjectAppropriate use criteria (AUC)en_US
dc.subjectMild cognitive impairment (MCI)en_US
dc.subjectPositron emission tomography (PET)en_US
dc.titleCritical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient careen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
main.pdf
Size:
259.31 KB
Format:
Adobe Portable Document Format
Description:
Main Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: